Pfizer buys biotech firm Seagen for $43 billion
Washington DC, 13/3: US pharmaceutical giant Pfizer announced Monday that it had reached a deal to buy biotech firm Seagen, specializing in innovative cancer treatment, for $43 billion. Pfizer is offering $229 per share in cash, and the companies expect to complete the transaction later this year or in early 2024, they said…
